Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
EAST RUTHERFORD, N.J., July 31, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that second quarter 2017 financial results will be released on Friday, August 4, 2017 before the market opens.
The Company will host a conference call to discuss the financial results.
| Second Quarter 2017 Earnings Conference Call | ||
| When: | Friday, August 4, 2017 at 8:30 a.m. Eastern Time | |
| Dial-in: | 1-866-548-4713 for U.S. | |
| 1-323-794-2093 for International | ||
| Passcode: 3908726 | ||
| Dial-in Replay: | 1-888-203-1112 for U.S. | |
| 1-719-457-0820 for International | ||
| Passcode: 3908726 | ||
| Available through Friday, August 11, 2017 | ||
| Webcast: | www.cambrex.com | |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201-804-3037 Email: [email protected]
